TBR Antibody

What is TBR-1 and what is its primary function in the nervous system?

TBR-1 is a neuron-specific transcription factor that plays a crucial role in brain development, particularly during embryogenesis. It helps define distinct regions that contribute to the paleocortex, limbic cortex, and neocortex. TBR-1 expression is primarily restricted to postmitotic cells, highlighting its importance in neuronal differentiation and maturation . As a transcriptional regulator, TBR-1 can function as both an activator and repressor of transcription, binding to target DNA loci via its T-box DNA-binding domain and recognizing the T-box binding element AGGTGTGA . It is also involved in neuronal migration, laminar and areal identity, and axonal projection during cortical development .

What types of TBR-1 antibodies are available for research applications?

Several types of TBR-1 antibodies are available for research, including:

• Monoclonal antibodies: Such as the mouse monoclonal IgG2b kappa TBR-1 antibody (G-5), which offers high specificity and reproducibility for consistent experimental results .

• Polyclonal antibodies: Including guinea pig and rabbit polyclonal antibodies that can recognize multiple epitopes on TBR-1, increasing sensitivity for detecting low-abundance proteins .

• Recombinant antibodies: Engineered for enhanced performance with batch-to-batch consistency, such as the rabbit monoclonal antibody [EPR8138(2)] .

These antibodies come in various formats, including non-conjugated forms and conjugated versions with agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates .

What are the common applications for TBR-1 antibodies in neuroscience research?

TBR-1 antibodies are valuable tools for multiple neuroscience research applications:

• Western blotting (WB): For quantitative analysis of TBR-1 protein expression

• Immunoprecipitation (IP): To study protein-protein interactions involving TBR-1

• Immunofluorescence (IF): For visualizing TBR-1 localization in cells and tissues

• Immunohistochemistry (IHC): To detect TBR-1 in tissue sections

• Enzyme-linked immunosorbent assay (ELISA): For quantitative detection of TBR-1

These applications allow researchers to investigate TBR-1's role in neuronal development, brain patterning, and neurodevelopmental disorders.

What criteria should be considered when selecting a TBR-1 antibody for specific experimental applications?

When selecting a TBR-1 antibody, researchers should consider:

• Application compatibility: Verify that the antibody has been validated for your intended application (WB, IHC, IF, etc.) .

• Species reactivity: Ensure the antibody recognizes TBR-1 in your species of interest (human, mouse, rat, etc.) .

• Epitope specificity: Consider the specific region of TBR-1 that the antibody targets, particularly if studying specific domains or variants .

• Clonality: Monoclonal antibodies offer higher specificity but recognize a single epitope, while polyclonal antibodies provide higher sensitivity by recognizing multiple epitopes .

• Format requirements: Determine if you need a conjugated antibody (HRP, fluorescent tags) or an unconjugated version .

• Validation data: Review existing publications and validation data to ensure reliability in your experimental context .

How can researchers validate the specificity of TBR-1 antibodies?

To validate TBR-1 antibody specificity:

• Positive and negative controls: Use tissues or cell lines known to express or lack TBR-1 expression, respectively. For instance, cerebral cortex samples should show positive nuclear staining, while most non-neuronal tissues should be negative .

• Knockout/knockdown validation: Compare antibody reactivity in wildtype samples versus TBR-1 knockout or knockdown samples to confirm specificity.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to samples. Specific binding should be blocked.

• Multiple antibody comparison: Use two or more antibodies targeting different TBR-1 epitopes and compare staining patterns.

• Western blot analysis: Confirm that the antibody detects a band of the expected molecular weight (approximately 74 kDa for TBR-1).

What are the optimal working dilutions for different TBR-1 antibodies across applications?

Optimal working dilutions vary by antibody clone and application. Based on available data:

What are the optimized protocols for using TBR-1 antibodies in immunohistochemistry of brain tissue?

Optimized IHC protocol for TBR-1 detection in brain tissue:

• Tissue preparation:

  • Fix tissue with 4% paraformaldehyde for 24 hours at 4°C

  • Process and embed in paraffin or prepare frozen sections (10-20 μm thick)

• Antigen retrieval:

  • For paraffin sections: Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) for 15-20 minutes

  • For frozen sections: This step may be optional

• Blocking and permeabilization:

  • Block with 5-10% normal serum (from the species of the secondary antibody) in PBS with 0.1-0.3% Triton X-100 for 1-2 hours at room temperature

• Primary antibody incubation:

  • Dilute TBR-1 antibody in blocking solution (see dilution table in section 2.3)

  • Incubate overnight at 4°C

• Secondary antibody detection:

  • Use appropriate species-specific secondary antibody

  • For chromogenic detection: Use HRP-conjugated secondary antibody followed by DAB

  • For fluorescent detection: Use fluorophore-conjugated secondary antibody

• Counterstaining and mounting:

  • Counterstain nuclei with hematoxylin (chromogenic) or DAPI/Hoechst (fluorescent)

  • Mount with appropriate medium

Note: TBR-1 should show nuclear localization in cortical neurons. Under some experimental conditions, weak cytoplasmic staining may be observed .

How can TBR-1 antibodies be used to investigate protein-protein interactions in neurodevelopmental research?

TBR-1 antibodies can be powerful tools for studying protein-protein interactions through several approaches:

• Co-immunoprecipitation (Co-IP):

  • Lyse cells/tissues in a non-denaturing buffer

  • Incubate lysates with TBR-1 antibody and protein A/G beads

  • Wash stringently and elute bound proteins

  • Analyze interacting partners by western blot or mass spectrometry

  • This approach has identified interactions between TBR-1 and proteins such as CASK, FOXP1/2/4, and BCL11A

• Proximity ligation assay (PLA):

  • Use TBR-1 antibody in combination with antibodies against suspected interaction partners

  • Apply species-specific PLA probes that generate a fluorescent signal when proteins are in close proximity (<40 nm)

  • This technique offers in situ visualization of protein interactions in fixed cells/tissues

• Bioluminescence resonance energy transfer (BRET) assays:

  • While not directly using antibodies, this complementary approach has validated TBR-1 interactions with GATAD2B, BCOR, ADNP, NR2F1, and NR2F2

  • These validated interactions can guide antibody-based co-IP experiments

• Chromatin immunoprecipitation (ChIP):

  • Use TBR-1 antibodies to identify DNA binding sites

  • Can be combined with mass spectrometry (ChIP-MS) to identify co-factors at specific genomic loci

  • TBR-1 binding sites identified by ChIP-seq are enriched for both active and repressive chromatin marks

What controls are essential when using TBR-1 antibodies for quantitative analyses?

For reliable quantitative analyses with TBR-1 antibodies, the following controls are essential:

• Primary antibody controls:

  • Positive control: Tissue/cells known to express TBR-1 (e.g., cerebral cortex)

  • Negative control: Tissue/cells known not to express TBR-1

  • No primary antibody control: Samples processed with secondary antibody only

  • Isotype control: Samples incubated with non-specific IgG of the same isotype

• Loading/normalization controls:

  • For Western blot: Include housekeeping proteins (β-actin, GAPDH, tubulin)

  • For immunostaining: Use reference markers and analyze cell counts relative to total (DAPI-positive) cells

• Technical controls:

  • Include biological replicates (different animals/patients)

  • Include technical replicates (multiple measurements from the same sample)

  • Standard curve using recombinant TBR-1 protein for absolute quantification

  • Peptide blocking controls to confirm specificity

• Expression modulation controls:

  • TBR-1 knockdown/knockout samples

  • Overexpression systems with tagged TBR-1 constructs

• Signal intensity calibration:

  • For fluorescence: Include calibration beads or standards

  • For colorimetric assays: Include standard curve

What are common issues encountered when using TBR-1 antibodies and how can they be resolved?

Note: Some TBR-1 antibodies may show weak cytoplasmic staining under certain conditions, as observed with the EPR8138(2) clone in human glioma samples .

How should researchers interpret contradictory results from different TBR-1 antibodies?

When faced with contradictory results from different TBR-1 antibodies:

• Review antibody characteristics:

  • Compare epitope regions targeted by each antibody

  • Consider antibody formats (monoclonal vs. polyclonal)

  • Check if antibodies recognize different TBR-1 isoforms or post-translational modifications

• Validate with orthogonal approaches:

  • Confirm TBR-1 expression using mRNA detection methods (qPCR, in situ hybridization)

  • Use TBR-1 overexpression or knockdown/knockout models

  • Apply multiple antibodies targeting different epitopes

• Scrutinize experimental conditions:

  • Different fixation methods may affect epitope accessibility

  • Sample preparation can influence protein conformation

  • Buffer conditions may impact antibody binding

• Consider biological context:

  • TBR-1 expression is developmentally regulated and cell-type specific

  • Protein interactions may mask certain epitopes

  • Post-translational modifications might affect antibody recognition

• Consult published literature:

  • Search for precedent of similar discrepancies

  • Contact authors who have successfully used specific antibodies

  • Consider forming a consensus view based on multiple studies

How can researchers differentiate between specific and non-specific binding when using TBR-1 antibodies?

To differentiate between specific and non-specific binding when using TBR-1 antibodies:

• Perform peptide competition assays:

  • Pre-incubate the antibody with excess immunizing peptide

  • Apply to parallel samples

  • Specific signals should be blocked, while non-specific binding will remain

• Compare multiple antibodies:

  • Use antibodies targeting different TBR-1 epitopes

  • Specific signals should be consistent across antibodies

  • Non-specific binding patterns typically differ between antibodies

• Include genetic controls:

  • Test antibody in TBR-1 knockout/knockdown models

  • Specific signals should be reduced or absent

  • Persistent signals in knockout samples indicate non-specific binding

• Analyze signal characteristics:

  • Specific TBR-1 binding should show nuclear localization in neurons

  • Evaluate whether the signal pattern matches known TBR-1 biology

  • Consider whether signal intensity correlates with expected expression levels

• Use blocking agents strategically:

  • Include additional blocking agents (BSA, non-fat milk, normal serum)

  • Test whether suspected non-specific signals can be eliminated

  • Optimize washing steps to reduce background

• Verify with recombinant protein:

  • Test antibody against purified recombinant TBR-1

  • Compare band patterns or staining with experimental samples

How can TBR-1 antibodies be used to investigate the role of TBR-1 variants in neurodevelopmental disorders?

TBR-1 antibodies can be powerful tools for investigating TBR-1 variants in neurodevelopmental disorders through several sophisticated approaches:

• Functional characterization of patient-derived variants:

  • Use TBR-1 antibodies to assess protein expression, localization, and stability of variant proteins in cellular models

  • Compare wildtype and variant TBR-1 protein levels and subcellular distribution using quantitative immunofluorescence and fractionation followed by western blotting

  • Patient variants have been characterized for their effects on subcellular localization, transcriptional repression, and protein interactions

• Protein-protein interaction analyses:

  • Use co-immunoprecipitation with TBR-1 antibodies to compare interaction profiles of wildtype versus variant TBR-1

  • Apply proximity ligation assays to visualize altered interactions in situ

  • BRET assays have demonstrated that five TBR-1 patient variants disrupt interactions with GATAD2B, BCOR, ADNP, and NR2F1/2

• Chromatin binding and transcriptional activity:

  • Employ ChIP-seq with TBR-1 antibodies to map genome-wide binding differences between wildtype and variant proteins

  • Combine with RNA-seq to correlate binding changes with transcriptional outcomes

  • TBR-1 binding sites from ChIP-seq show enrichment for both active (H2K27ac, H3K4me1) and repressive (H3K9me3, H3K27me3) chromatin marks

• In vivo modeling:

  • Generate knock-in models of patient variants and use TBR-1 antibodies to track expression during development

  • Apply immunohistochemistry to assess cortical layering and neuronal migration defects

• Developmental trajectory analysis:

  • Use stage-specific immunostaining to examine how variants affect the temporal dynamics of TBR-1 expression and function during brain development

What emerging techniques are enhancing the utility of TBR-1 antibodies in neuroscience research?

Several cutting-edge techniques are expanding the research applications of TBR-1 antibodies:

• Single-cell proteomics:

  • Coupling antibody-based detection with single-cell isolation techniques

  • Mass cytometry (CyTOF) using metal-conjugated TBR-1 antibodies for high-dimensional analysis

  • Identifies cell-specific expression patterns and heterogeneity within neuronal populations

• Super-resolution microscopy:

  • STORM, PALM, and STED microscopy with fluorophore-conjugated TBR-1 antibodies

  • Reveals nanoscale organization of TBR-1 within the nucleus and its co-localization with other transcription factors

  • Provides insights into chromatin-associated TBR-1 complexes at a resolution below the diffraction limit

• In situ protein interaction mapping:

  • Proximity labeling techniques (BioID, APEX) combined with TBR-1 antibodies

  • Identifies context-specific interactors in different brain regions or developmental stages

  • The TBR-1 interactome includes approximately 250 putative interaction partners identified by affinity purification coupled to mass spectrometry

• Spatial transcriptomics integration:

  • Combining TBR-1 immunohistochemistry with spatial transcriptomics

  • Correlates TBR-1 protein localization with downstream transcriptional effects in tissue context

  • Maps regional and layer-specific functions of TBR-1 in the developing cortex

• Live-cell imaging with intrabodies:

  • Engineered antibody fragments that work in living cells

  • Tracks TBR-1 dynamics during neuronal differentiation and migration

  • Visualizes real-time changes in TBR-1 localization in response to signaling events

How can TBR-1 antibodies be utilized to study the interplay between TBR-1 and other transcription factors in neuronal development?

TBR-1 antibodies offer powerful approaches to investigate transcription factor networks in neuronal development:

• Sequential ChIP (ChIP-reChIP):

  • Perform first ChIP with TBR-1 antibody, then re-immunoprecipitate with antibodies against other transcription factors

  • Identifies genomic loci co-occupied by TBR-1 and partners

  • Reveals cooperative or competitive binding relationships

• Co-immunoprecipitation coupled with mass spectrometry:

  • Use TBR-1 antibodies to pull down native protein complexes

  • Identify transcription factor partners in different developmental contexts

  • TBR-1 has been shown to interact with various transcription factors including FOXP1/2/4, BCL11A, GATAD2B, and NR2F1/2

• Multiplexed immunofluorescence:

  • Simultaneously detect TBR-1 and other transcription factors

  • Quantify co-expression patterns across brain regions and developmental stages

  • Analyze nuclear co-localization at single-cell resolution

• Targeted protein degradation approaches:

  • Combine degron-tagged TBR-1 with antibody detection of partner proteins

  • Measure how acute TBR-1 depletion affects partner localization and stability

  • Analyze temporal dynamics of transcription factor dependencies

• Chromatin conformation studies:

  • Integrate ChIP-seq using TBR-1 antibodies with Hi-C or 4C techniques

  • Map how TBR-1 influences 3D genome organization

  • Identify long-range interactions mediated by TBR-1 and partner factors

The TBR-1 interactome includes diverse functional protein clusters involved in transcriptional regulation, such as:

• Transcription factors and co-factors (FOXP1/2/4, GATAD2B, BCOR)

• Chromatin modifiers (KDM1A, SMARCA2)

• Nuclear receptor family members (NR2F1, NR2F2)

• Mediator complex members (MED12, MED23)

What strategies can improve the sensitivity and specificity of TBR-1 detection in challenging samples?

For challenging samples where TBR-1 detection may be difficult:

• Signal amplification techniques:

  • Tyramide signal amplification (TSA): Can increase sensitivity by 10-100 fold

  • Polymer-based detection systems: Provide enhanced signal with lower background

  • Quantum dot conjugates: Offer higher sensitivity and photostability compared to conventional fluorophores

• Epitope retrieval optimization:

  • Test multiple retrieval buffers (citrate, EDTA, Tris, etc.) at different pH values

  • Compare heat-induced (microwave, pressure cooker, water bath) vs. enzymatic retrieval

  • Optimize retrieval duration for specific sample types

  • Some TBR-1 epitopes may be particularly sensitive to fixation conditions

• Sample preparation refinements:

  • Adjust fixation protocols (duration, temperature, fixative concentration)

  • Test fresh frozen vs. fixed samples for epitope preservation

  • Consider specialized fixatives designed to preserve nuclear antigens

• Antibody cocktails:

  • Use combinations of TBR-1 antibodies targeting different epitopes

  • Apply monoclonal cocktails or monoclonal-polyclonal combinations

  • This strategy increases the probability of detecting TBR-1 despite epitope masking

• Background reduction techniques:

  • Pre-adsorption of secondary antibodies with tissue homogenates

  • Addition of detergents or carrier proteins to reduce non-specific binding

  • Use of specialized blocking reagents for problematic tissues

How should researchers approach batch-to-batch variation in TBR-1 antibodies?

To address batch-to-batch variation in TBR-1 antibodies:

• Standardized validation:

  • Implement a consistent validation protocol for each new antibody batch

  • Include western blot against recombinant TBR-1 and positive control tissues

  • Compare immunostaining patterns between old and new batches

  • Consider using recombinant antibodies like [EPR8138(2)] which offer improved batch-to-batch consistency

• Reference standards:

  • Maintain a bank of reference samples processed with previously validated batches

  • Process reference samples alongside experimental samples with new batches

  • Use identical positive controls across experiments for normalization

• Quantitative assessment:

  • Measure signal-to-noise ratios and dynamic range for each batch

  • Establish acceptance criteria for batch qualification

  • Document lot-specific optimal working dilutions

• Strategic purchasing:

  • Purchase larger quantities of a single batch for long-term studies

  • Request certificates of analysis from manufacturers

  • Consider vendor-validated lots with application-specific testing

• Parallel testing approach:

  • When transitioning to a new batch, run key experiments with both old and new batches

  • Calculate correction factors if necessary for quantitative analyses

  • Document batch-specific performance characteristics

What considerations are important when designing quantitative analyses of TBR-1 expression patterns across brain regions?

When designing quantitative analyses of TBR-1 expression patterns:

• Sampling strategy:

  • Implement systematic random sampling to avoid bias

  • Define anatomical boundaries consistently across specimens

  • Use stereological approaches for volumetric estimations

  • Include multiple sections spanning the regions of interest

• Normalization approaches:

  • Select appropriate internal controls (e.g., housekeeping proteins)

  • Consider cell density variations across brain regions

  • Account for developmental timing differences between regions

  • Normalize to total cell counts or tissue volume

• Quantification methods:

  • Automated image analysis with validated algorithms

  • Threshold determination strategies (manual vs. automated)

  • Fluorescence intensity measurements (integrated density, mean intensity)

  • Cell counting approaches (stereology, automated detection)

• Technical considerations:

  • Standardize image acquisition parameters (exposure, gain, offset)

  • Process all samples in parallel to minimize technical variation

  • Include fluorescence standards for absolute quantification

  • Account for tissue autofluorescence through spectral unmixing

• Statistical analysis plan:

  • Determine appropriate statistical tests based on data distribution

  • Calculate required sample sizes through power analysis

  • Implement mixed-effects models for nested data structures

  • Control for multiple comparisons when analyzing numerous brain regions

TBR-1 expression is developmentally regulated and varies significantly across brain regions, with highest expression in the cerebral cortex, particularly in layer 6 corticothalamic projection neurons, making careful quantification essential for meaningful comparisons .